By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Calistoga Pharmaceuticals 

2101 - 4th Avenue
Suite 1960
Seattle  Washington  98121  U.S.A.
Phone: 206-728-4700 Fax: 206-728-4777


SEARCH JOBS








Company News
Gilead Sciences, Inc. (GILD) to Acquire Calistoga Pharmaceuticals for $375 Million 2/22/2011 8:06:49 AM
Calistoga Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference 1/5/2011 9:10:25 AM
Calistoga Pharmaceuticals Announces Positive Clinical Results from Ongoing Single-Agent and Combination Trials of CAL-101 in Patients with Hematologic Malignancies 12/6/2010 10:17:20 AM
Calistoga Pharmaceuticals Announces Oral and Poster Presentations at American Society of Hematology Annual Meeting 11/30/2010 9:58:28 AM
Calistoga Pharmaceuticals Announces Oral and Poster Presentations at American Society of Hematology Annual Meeting 11/29/2010 10:11:30 AM
Calistoga Pharmaceuticals' Delta-Isoform-Selective PI3 Kinase Inhibitor CAL-101 Recognized as One of Windhover Information Inc.'s ‘Top 10 Oncology Projects to Watch' 10/27/2010 11:12:02 AM
Calistoga Pharmaceuticals to Present at Upcoming Investor Conferences 10/26/2010 10:24:14 AM
Calistoga Pharmaceuticals Announces Initiation of Phase 2 Trial of Delta-Isoform-Selective PI3 Kinase Inhibitor CAL-101 in Combination with Rituximab for the Treatment of Previously Untreated Elderly Patients with Chronic Lymphocytic Leukemia 10/19/2010 9:49:20 AM
Calistoga Pharmaceuticals Appoints Andrew Guggenhime as Chief Financial Officer 9/28/2010 10:30:29 AM
Calistoga Pharmaceuticals Appoints Langdon L. Miller, M.D., Executive Vice President, Research & Development 7/29/2010 8:38:36 AM
123
//-->